Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + pomalidomide maintenance after BCMA CAR-T in high-risk multiple myeloma
ChiCTR2600126595Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jun 2026
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib and pomalidomide in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Overall Response Rate and Progression-Free Survival (primary). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ixazomibpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600126595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126595.